19,475 Shares in XOMA Co. (NASDAQ:XOMA) Acquired by Ellsworth Advisors LLC

Ellsworth Advisors LLC purchased a new stake in XOMA Co. (NASDAQ:XOMA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,475 shares of the biotechnology company's stock, valued at approximately $516,000. Ellsworth Advisors LLC owned approximately 0.17% of XOMA as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock valued at $1,484,000 after acquiring an additional 1,968 shares during the last quarter. Rhumbline Advisers grew its position in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after purchasing an additional 1,334 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA in the 1st quarter valued at approximately $212,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of XOMA by 55.6% in the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 1,266 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Stock Performance

Shares of XOMA stock traded up $0.56 during trading hours on Friday, hitting $29.40. 9,888 shares of the company were exchanged, compared to its average volume of 20,949. The firm has a fifty day simple moving average of $27.86 and a 200 day simple moving average of $26.22. XOMA Co. has a 52-week low of $14.27 and a 52-week high of $30.50. The stock has a market capitalization of $342.19 million, a price-to-earnings ratio of -7.50 and a beta of 0.92. The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The business had revenue of $11.09 million for the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. Research analysts predict that XOMA Co. will post -1.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XOMA has been the subject of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $117.00 price objective on shares of XOMA in a report on Friday, September 20th. StockNews.com raised shares of XOMA from a "sell" rating to a "hold" rating in a research report on Wednesday, August 14th.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.